Esbriet (pirfenidone) or Ofev (nintedanib) treatment in adults with idiopathic pulmonary fibrosis (IPF) led to changes in blood markers reflecting reduced systemic inflammation and oxidative stress after 24 weeks of therapy, a small study found. …
Bridge Biotherapeutics and Boehringer Ingelheim ended a collaboration and license agreement to develop BBT-877, a potential treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic disorders. The companies entered into an agreement in July 2019 and, although no details were provided about its termination, the…
Galapagos and OncoArendi Therapeutics have entered into an exclusive agreement for the global development and commercialization of OncoArendi’s OATD-01, an investigational treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Lung diseases like IPF are characterized by increased activity of enzymes called…
Use of the well-known anticoagulant therapy warfarin in people with idiopathic pulmonary fibrosis (IPF) is associated with reduced transplant-free survival, but direct oral anticoagulants (DOACs) are not, a study found. While…
A real-world analysis found that idiopathic pulmonary fibrosis (IPF) patients with preserved lung function benefitted from treatment with Ofev (nintedanib) and Esbriet (pirfenidone) over three years. Despite untreated patients entering this study…
Lung cancer contributes to a poor prognosis in patients with idiopathic pulmonary fibrosis (IPF), a new study indicates. The finding suggests that healthcare professionals should monitor the development and progression of cancer in patients with IPF, given its negative impact on prognosis. The study, “Prognostic impact of malignant…
FibroGen’s experimental antifibrotic therapy pamrevlumab may be more effective than Esbriet (pirfenidone) and Ofev (nintedanib) at slowing disease progression in people with idiopathic pulmonary fibrosis (IPF), according to a review study. Combined data from eight clinical trials showed that all three therapies significantly…
The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of free virtual workshops in December, with the aim of empowering leaders to start non-profit organizations and research programs to help people with rare diseases. “The RareLaunch program is…
A photo of a bespectacled young boy, his red baseball cap slightly askew as he enjoys time outside, will be featured on the front cover of an upcoming calendar in the “Same But Different” contest to raise awareness about rare disorders. “A Lovely Day Out in Kew Gardens,”…
The combination of CB5138-2 — an experimental peptide, or small protein — and Ofev (nintedanib) reduced symptoms of idiopathic pulmonary fibrosis (IPF) better than Ofev alone in a preclinical study. Together, CB5138-2 (developed by CohBar) and Ofev (an approved IPF therapy marketed by Boehringer Ingelheim)…
Get regular updates to your inbox.
